Skip to main content
TipRanks
Go Ultimate75% OFF

Eagle Pharmaceuticals (EGRX) Ratios

213 Followers

Eagle Pharmaceuticals Ratios

EGRX's free cash flow for Q2 2023 was $-132.00K. For the 2023 fiscal year, EGRX's free cash flow was decreased by $-6.00K and operating cash flow was $-126.00K. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 22Dec 21Dec 20Dec 19Dec 18
Liquidity Ratios
Current Ratio1.702.324.364.624.13
Quick Ratio1.272.034.154.453.92
Cash Ratio0.501.312.712.831.99
Solvency Ratio0.28-0.060.250.250.46
Operating Cash Flow Ratio0.460.381.301.441.32
Short-Term Operating Cash Flow Coverage8.111.106.1911.208.38
Net Current Asset Value$ 16.15M$ 95.33M$ 98.89M$ 104.07M$ 86.00M
Leverage Ratios
Debt-to-Assets Ratio0.170.120.150.150.19
Debt-to-Equity Ratio0.290.170.210.220.28
Debt-to-Capital Ratio0.220.140.170.180.22
Long-Term Debt-to-Capital Ratio0.190.000.120.160.19
Financial Leverage Ratio1.741.441.361.421.48
Debt Service Coverage Ratio5.02-0.121.832.824.26
Interest Coverage Ratio20.011.6912.798.1213.38
Debt to Market Cap0.170.040.050.050.07
Interest Debt Per Share5.552.413.033.003.19
Net Debt to EBITDA0.16-80.09-2.16-2.43-0.85
Profitability Margins
Gross Profit Margin70.01%75.41%75.79%68.91%70.97%
EBIT Margin20.68%-1.70%13.45%12.60%17.24%
EBITDA Margin24.48%0.49%15.98%14.98%18.96%
Operating Profit Margin25.57%1.61%17.55%11.14%17.17%
Pretax Profit Margin19.40%-2.65%12.07%11.23%15.96%
Net Profit Margin11.26%-5.03%6.38%7.31%14.96%
Continuous Operations Profit Margin11.26%-5.03%6.38%7.31%14.96%
Net Income Per EBT58.02%189.69%52.87%65.07%93.73%
EBT Per EBIT75.88%-164.25%68.81%100.84%92.96%
Return on Assets (ROA)8.78%-3.40%4.74%5.62%13.37%
Return on Equity (ROE)15.26%-4.89%6.45%7.99%19.84%
Return on Capital Employed (ROCE)27.44%1.54%15.32%10.11%18.41%
Return on Invested Capital (ROIC)15.51%1.34%7.77%6.43%16.73%
Return on Tangible Assets14.68%-4.24%5.98%7.18%17.65%
Earnings Yield9.43%-1.30%1.91%1.73%5.36%
Efficiency Ratios
Receivables Turnover4.314.133.674.083.21
Payables Turnover5.002.577.2511.156.24
Inventory Turnover1.991.935.639.277.46
Fixed Asset Turnover271.07104.8690.4288.9688.99
Asset Turnover0.780.680.740.770.89
Working Capital Turnover Ratio3.601.521.401.481.61
Cash Conversion Cycle195.40135.69113.8596.06104.26
Days of Sales Outstanding84.6688.2999.3589.44113.76
Days of Inventory Outstanding183.75189.5864.8339.3548.95
Days of Payables Outstanding73.02142.1850.3232.7458.46
Operating Cycle268.42277.87164.18128.80162.72
Cash Flow Ratios
Operating Cash Flow Per Share3.922.163.674.073.55
Free Cash Flow Per Share3.912.143.624.013.54
Dividend Paid and CapEx Coverage Ratio284.8487.3766.2672.05393.86
Capital Expenditure Coverage Ratio284.8487.3766.2672.05393.86
Operating Cash Flow Coverage Ratio0.750.951.301.451.18
Operating Cash Flow to Sales Ratio0.160.160.260.290.25
Free Cash Flow Yield13.36%4.20%7.76%6.68%8.78%
Valuation Ratios
Price-to-Earnings (P/E) Ratio10.61-77.0352.3757.7418.65
Price-to-Sales (P/S) Ratio1.193.873.344.222.79
Price-to-Book (P/B) Ratio1.623.773.384.613.70
Price-to-Free Cash Flow (P/FCF) Ratio7.4823.8212.8814.9711.39
Price-to-Operating Cash Flow Ratio7.4623.5512.6814.7611.36
Price-to-Earnings Growth (PEG) Ratio-0.020.44-3.63-1.11-0.50
Enterprise Value Multiple5.04704.5118.7525.7413.86
Enterprise Value390.53M596.72M562.90M755.15M560.64M
EV to EBITDA5.04704.5118.7525.7413.86
EV to Sales1.233.483.003.852.63
EV to Free Cash Flow7.7321.3911.5513.6810.73
EV to Operating Cash Flow7.7021.1511.3713.4910.70
Tangible Book Value Per Share5.439.669.899.006.97
Shareholders’ Equity Per Share18.0613.5213.8013.0310.89
Tax and Other Ratios
Effective Tax Rate0.42-0.900.470.350.06
Revenue Per Share24.4813.1413.9314.2414.44
Net Income Per Share2.76-0.660.891.042.16
Tax Burden0.581.900.530.650.94
Interest Burden0.941.560.900.890.93
Research & Development to Revenue0.110.300.160.190.21
SG&A to Revenue0.310.390.400.380.27
Stock-Based Compensation to Revenue0.050.110.130.110.09
Income Quality1.42-3.274.133.911.64

Currency in USD